A Phase 1/1b Study of IAM1363 in HER2 Cancers | MicrobiomeTrials← Back to trialsNCT06253871
A Phase 1/1b Study of IAM1363 in HER2 Cancers
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2024-03-25Est. Completion: 2027-12
Enrollment target: 383 participants Locations- UCSD Moores Cancer Center, La Jolla, California, United States
- USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
- University of Colorado Cancer Center, Aurora, Colorado, United States
- University of Miami, Miami, Florida, United States
- Comprehensive Hematology Oncology, St. Petersburg, Florida, United States
- University of Chicago, Chicago, Illinois, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
- University of Michigan, Ann Arbor, Michigan, United States
- Henry Ford Cancer Institute, Detroit, Michigan, United States
- START - Midwest Cancer Research Center, Grand Rapids, Michigan, United States
- Saint Luke's Cancer Institute, Kansas City, Missouri, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- Dartmouth Hitchcock Medical, Lebanon, New Hampshire, United States
- Rutgers Cancer Institute, New Brunswick, New Jersey, United States
Other microbiome trials you might be interested in
Metastatic Breast Cancer
This is an umbrella study evaluating the efficacy and safety of multiple treatment combinations in participants with met…
Duarte, United StatesEst. completion Sep 30, 2030
Advanced Non-small Cell Lung Cancer, HER2 Mutation
Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC) with speci…
Newport Beach, United StatesEst. completion Oct 28, 2027
Icahn School of Medicine at Mount Sinai, New York, New York, United StatesDuke Cancer Institute, Durham, North Carolina, United StatesUniversity Hospital Cleveland Medical Center, Cleveland, Ohio, United StatesCleveland Clinic, Cleveland, Ohio, United StatesOU Health Stephenson Cancer Center, Oklahoma City, Oklahoma, United StatesProvidence Cancer Institute, Portland, Oregon, United StatesSCRI Oncology Partners, Nashville, Tennessee, United StatesVanderbilt Ingram Cancer Center, Nashville, Tennessee, United StatesNEXT Oncology - Austin, Austin, Texas, United StatesMary Crowley Cancer Research, Dallas, Texas, United StatesMD Anderson Cancer Center - University of Texas, Houston, Texas, United StatesSTART Mountain Region, West Valley City, Utah, United StatesNEXT Oncology - Virginia Cancer Specialists, Fairfax, Virginia, United StatesFred Hutchinson Cancer Center, Seattle, Washington, United StatesCentre Georges François Leclerc, Dijon, FranceInstitut de Cancerologie de l'Ouest, Saint-Herblain, FranceInstitut Universitaire du Cancer de Toulouse (IUCT) Oncopole Institut Claudius Regaud ", Toulouse, FranceThe START center Dublin, Dublin, Dublin, IrelandCork University Hospital, Wilton, Cork, IrelandSt. Vincent's University Hospital, Dublin, IrelandAzienda Ospedaliero Universitaria Careggi - Largo Giovanni Alessandro Brambilla 3, Florence, ItalyIstituto Europeo di Oncologia (IEO), Milan, ItalyGrande Ospedale Metropolitano Niguarda, Milan, ItalyAzienda Ospedaliera Universitaria Luigi Vanvitelli, Naples, ItalyNetherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, NetherlandsSeoul National University Hospital, Seoul, South KoreaSeverance Hospital - Yonsei Cancer Center, Seoul, South KoreaAsan Medical Center, Seoul, South KoreaSamsung Medical Center, Seoul, South KoreaHospital Universitario Vall dHebron, Barcelona, SpainHospital Universitario 12 de Octubre, Madrid, SpainSTART Madrid CIOCC, Hospital Universitario HM Sanchinarro, Madrid, SpainHospital Universitario Regional Málaga, Málaga, SpainHospital Universitario Virgen del Rocio, Seville, SpainHospital Clinico Universitario de Valencia (INCLIVA), Valencia, SpainRoyal Marsden NHS Foundation Trust, Royal Marsden Hospital (RMH)/Chelsea), Chelsea, United KingdomOxford University Hospitals NHS Foundation Trust Churchill Hospital, Oxford, United KingdomRoyal Marsden NHS Foundation Trust, Royal Marsden Hospital (RMH)/Sutton, Sutton, United KingdomAdvanced Malignant Solid NeoplasmAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Locally Advanced Malignant Solid NeoplasmMalignant Female Reproductive System NeoplasmMetastatic HER2-Negative Breast CarcinomaMetastatic Malignant Solid NeoplasmRecurrent Endometrial CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Malignant Female Reproductive System NeoplasmRecurrent Malignant Solid NeoplasmRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal CarcinomaUnresectable HER2-Negative Breast CarcinomaUnresectable Malignant Solid Neoplasm
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment…
Birmingham, United StatesEst. completion Jul 1, 2030